Please ensure Javascript is enabled for purposes of website accessibility

Will Varian Medical Systems Beat These Analyst Estimates?

By Seth Jayson – Updated Apr 10, 2017 at 1:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Checking expectations

Varian Medical Systems (NYSE: VAR) is expected to report Q2 earnings on April 24. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Varian Medical Systems's revenues will grow 5.2% and EPS will grow 6.3%.

The average estimate for revenue is $758.0 million. On the bottom line, the average EPS estimate is $1.02.

Revenue details
Last quarter, Varian Medical Systems logged revenue of $678.4 million. GAAP reported sales were 8.5% higher than the prior-year quarter's $625.3 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at $0.89. GAAP EPS of $0.86 for Q1 were 8.9% higher than the prior-year quarter's $0.79 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 42.9%, 10 basis points worse than the prior-year quarter. Operating margin was 20.9%, 30 basis points better than the prior-year quarter. Net margin was 14.0%, 40 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $3.04 billion. The average EPS estimate is $4.12.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 386 members out of 401 rating the stock outperform, and 15 members rating it underperform. Among 115 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 112 give Varian Medical Systems a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Varian Medical Systems is outperform, with an average price target of $72.71.

Is Varian Medical Systems the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Varian Medical Systems Stock Quote
Varian Medical Systems
VAR

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
371%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.